Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06765668 · ClinicalTrials.gov registry record · Phase 4
A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease
A Phase 4 study of Parkinson Disease, sponsored by Impax Laboratories.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 220
- Enrollment target
- 20
- Study locations
NCT06765668: Recruiting Phase 4 study of Parkinson Disease, sponsored by Impax Laboratories.
NCT06765668 is a Phase 4 study of Parkinson Disease that is actively recruiting participants, run by Impax Laboratories. The registered enrollment target is 220 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06765668, a Phase 4 study of Parkinson Disease, is actively recruiting participants, sponsored by Impax Laboratories.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 220 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).
Primary Outcome
"GOOD ON" time is derived from the 3-day Parkinson's disease (PD) diaries. For each day, "GOOD ON" time is calculated by adding the number of half-hour intervals in which either an "on time without dyskinesia" or "on time with non-troublesome dyskinesia" is checked.
Conditions Studied
Interventions
- DRUG CREXONT ER
Study Locations (20)
Florida
- Visionary Investigators Network - Aventura
- Parkinsons Disease and Movement Disorders Center of Boca Raton - Boca Raton
- Univesity of Miami - Miller School of Medicine - Boca Raton
- University of Miami - Miami
- N1 Research LLC - Orlando
- USF Parkinson's Disease and Movement Disorders Center - Tampa
Ohio
- NeuroScience Research Center, LLC - Canton
- University of Cincinnati - Cincinnati
- University Hospitals Cleveland Medical Center - Cleveland
California
- Parkinson's Research Centers of America - Orange County - Aliso Viejo
- Parkinson's Research Centers of America - Palo Alto - Palo Alto
Arizona
- Barrow Neurological Institute - Phoenix
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
Illinois
- Central DuPage Hospital - Movement Disorders Center - Winfield
Kansas
- University of Kansas Medical Center - Kansas City
Michigan
- Quest Research Institute - Farmington Hills
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2025-02-12 |
| Est. Completion | 2026-08-06 |
| Phase | Phase 4 |
What NCT06765668 shows while recruiting
NCT06765668 is an interventional study that assigns participants to a tested intervention. The registered 220 participants enrollment target is mid-sized for trials with a published cap, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 1 intervention - of which CREXONT ER is the first listed.
NCT06765668 names 20 study sites across 12 states, led by Florida, Ohio, California.
Frequently Asked Questions
What is clinical trial NCT06765668 about?
NCT06765668 is a clinical study titled "A Study of CREXONT (Carbidopa and Levodopa) Extended-Release Capsules in Participants With Parkinson's Disease". The primary purpose of this study is to evaluate efficacy and safety of CREXONT under real world conditions in participants with Parkinson disease (PD).
What is the current status of trial NCT06765668?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 220 participants. The study started on 2025-02-12. Estimated completion is 2026-08-06.
What conditions does trial NCT06765668 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT06765668?
The interventions under investigation include: CREXONT ER (DRUG).
Who is sponsoring clinical trial NCT06765668?
This trial is sponsored by Impax Laboratories, which has 19 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06765668 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06765668's enrollment target sits among peer trials
220 43rd of 297 higher than 255 of 297 other Parkinson Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Parkinson Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
BOOST-PD A Naturalistic Study on IPX-203 for Parkinson's Disease
RECRUITING · Phase 4
-
Cortical Electrophysiology of Response Inhibition in Parkinson's Disease
RECRUITING · Phase 4
-
Personalized Real-Time DBS and PD Mechanisms
RECRUITING · Phase 4
-
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
RECRUITING · Phase 4
-
Trial of Parkinson's And Zoledronic Acid
ACTIVE NOT RECRUITING · Phase 4
-
Treatment of REM Sleep Behavior Disorder (RBD) With Sodium Oxybate
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00920972 · 220 participants · Phase 1
Campath/Fludarabine/Melphalan Transplant Conditioning for Non-Malignant Diseases
- NCT01851642 · 220 participants
Lung Disease and Its Affect on the Work of White Blood Cells in the Lungs
- NCT02582021 · 220 participants
WISE CVD - Continuation (WISE HFpEF)
- NCT04067830 · 220 participants · Phase 2
Respiratory Muscle Training Before Surgery in Preventing Lung Complications in Patients With Stage I-IIIB Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI